Sarin Jussi, Grénman Reidar, Aitasalo Kalle, Pulkkinen Jaakko
Department of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital and University of Turku, Turku, Finland.
Ann Otol Rhinol Laryngol. 2012 Sep;121(9):563-9. doi: 10.1177/000348941212100901.
We evaluated the results of cases of chronic otitis media treated with mastoid obliteration surgery using bioactive glass S53P4.
Twenty-five patients with chronic otitis media and 1 patient with cerebrospinal fluid leakage without chronic infection were treated with bioactive glass S53P4. Twenty patients had had previous surgery because of chronic otitis media with or without cholesteatoma. A mastoid obliteration was performed with bioactive glass S53P4 granules and a musculoperiosteal flap with or without bone paté. In 2 patients with a bony dehiscence at the middle cranial fossa, a bioactive glass plate was used to support the protruding dura. In addition, in 3 patients, occlusion of a dural fistula was needed The median follow-up period was 34.5 months (range, 1 to 182 months).
Excluding the 2 patients with only 1 month of follow-up at our department, 96% of the patients had a dry, safe ear or only intermittent otorrhea. In 92% of the patients, the objective of achieving a smaller or nonexistent cavity was achieved.
Bioactive glass S53P4 is a noteworthy material in mastoid obliteration surgery.
我们评估了使用生物活性玻璃S53P4进行乳突填充手术治疗慢性中耳炎病例的结果。
25例慢性中耳炎患者和1例无慢性感染的脑脊液漏患者接受了生物活性玻璃S53P4治疗。20例患者因慢性中耳炎伴或不伴胆脂瘤曾接受过手术。使用生物活性玻璃S53P4颗粒和带或不带骨糊的肌骨膜瓣进行乳突填充。在2例中颅窝骨质缺损患者中，使用生物活性玻璃板支撑突出的硬脑膜。此外，3例患者需要封闭硬脑膜瘘。中位随访期为34.5个月（范围1至182个月）。
排除在我科仅随访1个月的2例患者，96%的患者耳干、安全或仅有间歇性耳漏。92%的患者实现了缩小或消除术腔的目标。
生物活性玻璃S53P4在乳突填充手术中是一种值得关注的材料。
